Entresto Tablets and Granules for Pediatric Specified Drug-use Survey (Pediatric Chronic Heart Failure)

Prior treatment

• Patients who have received drugs containing the same ingredient as Entresto (including investigational products and drugs for post-marketing clinical study)
• Patients for whom Entresto is contraindicated according to the package insert
  • Patients with a history of hypersensitivity to any ingredients of Entresto
  • Patients currently under treatment with angiotensin-converting enzyme inhibitors or within 36 hours of discontinuation of treatment with angiotensin-converting enzyme inhibitors (alacepril, imidapril hydrochloride, enalapril maleate, captopril, quinapril hydrochloride, cilazapril hydrate, temocapril hydrochloride, delapril hydrochloride, trandolapril, benazepril hydrochloride, perindopril erbumine, lisinopril hydrate).
  • Patients with a history of angioedema (including angioedema due to angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors, hereditary angioedema, acquired angioedema, and idiopathic angioedema etc.)
  • Patients with diabetes mellitus under treatment with aliskiren fumarate (excluding patients with markedly poorly controlled blood pressure despite other antihypertensive therapies)
  • Patients with severe hepatic impairment (Child-Pugh class C)
  • Pregnant women or women who may be pregnant

• Written informed consent by a legally acceptable representative must be obtained before the start of treatment with Entresto.
• Patients who received Entresto for the first time under the indication of chronic heart failure
• Pediatric patients aged 1 to \< 18 years old at the start of treatment with Entresto